What We Do

Growth through Commercial Deals

Year Deal
2010 Company Founded
2011 Pipeline deal  - Institute of Cancer Therapeutics (ICT)
2012

Acquisition of EP0015 (VDA - ICT pipeline)

2014 Acquisition of Onco-NX Ltd (Equin programme)
2014 Acquisition of Duo-C technology (ICT pipeline)
2014 Acquisition of Spear Therapeutics Ltd (Duo-C programme)
2015 Acquisition of EP0015 (theranostic - ICT pipeline)
2016 Acquisition of EP0015 (taxane - ICT pipeline)
2017 Out-licensing of EP0015 to Ellipses Pharma Ltd
2018 Pipeline Extension, ICT
2018 Acquisition of Sol